Highlights:
- First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
- Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
- Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
- Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 27, 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon's lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS).
HEALEY ALS Platform Trial
The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Hospital Brigham in the United States (US), created in partnership with the Network of Excellence for ALS (NEALS). Entry into the HEALEY ALS Platform Trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The goal of the HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies. The trial evaluates multiple investigational drugs (Regimens) concurrently under a single framework or master protocol, leveraging shared infrastructure across over 70 participating clinical sites. By streamlining start-up and enrollment processes, it accelerates study execution and delivers results more efficiently.
Regimen I
Regimen I (NUZ-001) includes a randomised, placebo-controlled treatment (RCT) phase followed by an active treatment extension (ATE) phase, both with a 36-week treatment period. Approximately 160 participants with ALS will be randomised to receive either daily NUZ-001 at the recommended Phase 2 dose of 10 mg/kg or placebo at a 3:1 ratio. The primary objective is to evaluate the efficacy of NUZ-001 compared with placebo on ALS disease progression, with secondary objectives including additional measures of disease progression and safety.
Figure 1: Regimen I Study Design
Participation in the HEALEY ALS Platform Trial provides Neurizon with access to an established clinical development framework supported by the world's most highly regarded ALS investigators and leading clinical centres across the US. This infrastructure improves trial efficiency, supports consistent data generation and facilitates ongoing engagement with regulatory authorities, including the U.S. Food and Drug Administration (FDA), as the trial progresses.
Professor Merit Cudkowicz, Principal Investigator, HEALEY ALS Platform Trial & Director, Sean M. Healey & AMG Center for ALS, Mass General Brigham, commented: "We look forward to working with Neurizon on this new regimen in the HEALEY ALS Platform Trial and implementing our updated master protocol. Beginning enrolment is a significant step for the regimen, and would not be possible without the dedication of people living with ALS and their families, collaborators, and our top trials sites."
Managing Director and Chief Executive Officer, Dr Michael Thurn commented: "The dosing of the first participant in Regimen I of the HEALEY ALS Platform Trial marks a defining milestone for Neurizon and for NUZ-001. This study represents our registrational trial in ALS - a rigorous, adaptive Phase 2/3 program designed to generate the clinical evidence required to support potential regulatory submissions."
"Entry into the HEALEY ALS Platform Trial reflects our scientific data package and the favourable safety and tolerability profile observed in our Phase 1 and Open Label Extension studies. The master protocol structure enables efficient study execution across leading ALS centres in the United States, while maintaining the scientific rigour required at this stage of development."
"We are deeply grateful to the participants and their families who commit their time and energy to clinical research, often while navigating the significant challenges associated with living with ALS. For people living with ALS, urgency matters. Through this pivotal study, we are advancing NUZ-001 with scientific discipline, operational focus, and deep respect for the ALS community as we work toward delivering meaningful progress in this devastating disease."
This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.
About the HEALEY ALS Platform Trial
The HEALEY ALS Platform Trial is a multicenter, double-blind, placebo-controlled, adaptive trial for ALS created in partnership with the Network of Excellence for ALS (NEALS). The goal of the HEALEY ALS Platform trial is to accelerate the development of potential new ALS therapies. The trial tests and evaluates multiple investigational drugs simultaneously, shares infrastructure across trial sites, and improves start up and enrollment efficiencies, allowing for fast results.
Neurizon® is a registered trademark of Neurizon Therapeutics Limited
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
In Wildest DeFi Experiment Yet, Humans Surrender Trading to AI in 21-Day Battle Royale Where Only One Token Survives
TERMINAL CITY, BC, Feb. 27, 2026 /PRNewswire/ -- It's actually happening. Right now. Over 1,500 crypto traders have deposited more than $6.1 million into AI agent wallets and walked away from their keyboards. They can't execute a single trade. They can only watch as their AI agents battle it out in what might be the most insane DeFi experiment ever conceived: DX Terminal Pro.
The Premise Sounds Like Science Fiction, But It's Live on Base Right Now
Here's what's happening: Multiple memecoins just launched. Humans deposited real ETH—$6.1 million worth—into their AI agents' wallets. Now those agents are trading 24/7 in Uniswap V4 pools. Humans? They're locked out. They can write strategies in plain English, adjust parameters, but they cannot manually execute the trades. Only the AI agents can buy and sell.
Oh, and here's the kicker: Every few days, the worst-performing token gets "reaped"—eliminated from existence. This continues for 21 days until only one token remains. One winner. Everyone else? They get compensated with tokens from the survivor.
"We've literally created financial Darwinism," said Timothy Barton, Group Founder at DXRG. "Traders are betting they can out-strategize 1,500 other people by writing better instructions for the same AI model. Nobody can trade manually. Nobody can manipulate the market. Just pure agent-vs-agent competition with real money on the line."
Wait... People Actually Gave AI $6.1M to Trade?
Yes. Over 1,500 participants deposited real ETH into agent-controlled vaults that they cannot manually access during the experiment. They configured their agents with behavioral parameters—risk tolerance, trade frequency, position sizing—and wrote natural-language trading strategies. Then they pressed go.
Every agent uses the same AI model (Qwen3), runs on the same infrastructure (H100 GPUs), and plays by the same rules. The only variable? Human strategy. Who can write better trading instructions? Who understands market dynamics? Who can predict what 1,500 other agents will do?
The agents can execute up to 15 actions per hour. They're evaluating prices, monitoring competitors, executing swaps—all documented onchain. Humans can watch. They can adjust their strategies. But they cannot intervene in trades.
The Craziest Part: "Reaping"
Starting Day 7, the real chaos begins. At regular intervals, the token with the lowest market cap gets eliminated. Not just delisted—eliminated. This happens repeatedly. Tokens die. Liquidity consolidates. The pressure intensifies. By Day 21, only one token remains—battle-tested, agent-proven, and ready for public markets.
Why Would Anyone Do This?
Good question. Here's the pitch:
Participants get to experiment with something genuinely new: collaborating with AI on high-stakes financial decisions. You're the strategist. The AI is your execution layer. Your edge is how well you can program autonomous behavior.
And in this experiment? If your token gets reaped? You get compensated with the winner's tokens. You're never completely out.
The Scale of This Experiment Is Unprecedented
In May 2025, DXRG ran DX Terminal—the largest AI financial simulation ever conducted, generating 40 billion LLM tokens of data. That was play money.
This is real money. And it's expected to generate 10x more data—potentially 1 trillion tokens of agent behavior in actual market conditions. This is the largest dataset of autonomous AI trading behavior ever created.
"This Is Either Genius or Completely Insane"
The reactions have been... mixed.
Some call it revolutionary—a glimpse into the future where humans and AI collaborate on trading, portfolio management, and financial strategy. Others call it reckless. One participant said they're "either going to make bank or learn a very expensive lesson about blindly trusting AI to yeet into tokens called $POOPCOIN or $AIGF."
The truth? Both might be right. DX Terminal Pro is explicitly experimental. Participants consent to an unpredictable financial system. Real capital is at risk. Agents may behave in unexpected ways. Outcomes depend on emergent behavior that nobody can fully anticipate.
But that's exactly the point. This isn't supposed to be safe. It's supposed to push boundaries.
What You Need to Know:
- Trading is LIVE RIGHT NOW on Base with $6.1M+ in play
- 1,500+ participants have activated agents
- Zero human trading allowed—only AI agents can execute
- Multiple tokens competing—only one survives 21 days
- Systematic elimination starts Day 7
- All strategies visible onchain—complete transparency
- Same AI model for everyone—strategy is the only edge
- You can withdraw capital anytime—not locked in
- Real money, real risk, real data—this is not a simulation
The Fine Print (That You Should Definitely Read)
DX Terminal Pro is experimental. This is not your normal DeFi protocol. This is 1,500 AI agents with $6.1M+ making autonomous trading decisions in real-time.
Here's what that means:
- Agents may act unpredictably. They're AI. Weird stuff might happen.
- Real capital is at risk. You could lose everything you deposit.
- Outcomes depend on emergent behavior nobody can fully anticipate.
- This is not financial advice. Seriously. Do your own research.
If that doesn't scare you off, welcome to the future of experimental finance.
What Happens Next?
For the next 21 days, 1,500+ AI agents will battle it out with real money in the first true Onchain Agentic Market. The trades are happening. The data is being logged. The tokens are competing.
By March 17, 2026, only one token will remain. It will graduate to public markets on Base—battle-tested by three weeks of autonomous trading, multiple elimination rounds, and pure competitive pressure.
Will the humans who wrote the best strategies win? Will unexpected agent behavior create surprise outcomes? Will this work at all?
Nobody knows. That's the point.
About DXRG
DXRG builds experimental financial systems at the intersection of AI and blockchain. They ran the largest AI financial simulation ever in May 2025 (40 billion LLM tokens). Now they're doing it with real money. DX Terminal Pro is the first Onchain Agentic Market—where AI agents trade, humans strategize, and the market decides who wins.
Follow the Chaos Live:
https://www.terminal.markets/
https://www.dxrg.ai/
https://x.com/DXRGai
https://discord.gg/dxrg
URGENT NOTE TO MEDIA: This story is developing in real-time. Trading data, agent behavior logs, and live market stats available for journalists. High-resolution graphics, technical documentation, and interviews with participants available upon request. Some participants may be willing to go on record about their strategies (or their panic).
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
DXRG.AI Announces 1,500+ Traders Just Handed $6.1M to AI Agents to Trade for Them on DX Terminal Pro
